vTv Therap | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.08.

EBIT: As of FY2025 Q3, the actual value is USD -11.09 M.

Cash Position

• As of September 30, 2025, vTv Therapeutics Inc. had a cash position of $98.5 million, compared to $36.7 million as of December 31, 2024.

Research & Development (R&D) Expenses

• R&D expenses for the three months ended September 30, 2025, were $7.0 million, up from $3.2 million for the same period in 2024. This increase was due to higher spending on cadisegliatin and other projects, as well as increased indirect costs related to the Novo Nordisk license milestone accrual and payroll and share-based expenses.

General & Administrative (G&A) Expenses

• G&A expenses were $3.7 million for the three months ended September 30, 2025, compared to $3.3 million for the same period in 2024. The increase was primarily due to higher payroll and legal expenses.

Net Loss

• The net loss attributable to vTv shareholders for the three months ended September 30, 2025, was $8.7 million or $1.08 per basic share, compared to a net loss of $4.8 million or $0.88 per basic share for the same period in 2024.

Operating Loss

• The operating loss for the three months ended September 30, 2025, was $10.7 million, compared to $6.5 million for the same period in 2024.

Outlook / Guidance

• vTv Therapeutics Inc. expects to report topline results from the Phase 3 CATT1 trial in the second half of 2026. The company has strengthened its balance sheet with an $80 million private placement to support the completion of this trial.